Reuters logo
BRIEF-Rigel Pharmaceuticals provides updates and preliminary data in IGA Nephropathy
January 5, 2017 / 12:43 PM / 10 months ago

BRIEF-Rigel Pharmaceuticals provides updates and preliminary data in IGA Nephropathy

Jan 5 (Reuters) - Rigel Pharmaceuticals Inc

* Rigel provides business updates and preliminary data in IGA Nephropathy

* Rigel Pharmaceuticals sees to submitting New Drug Application to U.S. Food and Drug Administration for fostamatinib in chronic ITP in Q1 of this year

* Rigel Pharma- expects second cohort, evaluating higher dose of fostamatinib (150 mg) for IGAN, to finish enrollment in 2017, full results in 2018

* Rigel Pharma- expects to end 2016 with about $74.8 million in cash, cash equivalents, short-term investments believes to be sufficient to fund operations into 2018 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below